Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $12.77 Consensus Target Price from Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received a consensus recommendation of “Buy” from the fourteen brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $12.7692.

A number of research firms recently weighed in on TSHA. Citizens Jmp restated a “market outperform” rating and issued a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, July 2nd. Needham & Company LLC reiterated a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, June 30th. Robert W. Baird lifted their price target on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Bank of America boosted their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Finally, Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the transaction, the insider owned 936,410 shares in the company, valued at approximately $5,843,198.40. The trade was a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company’s stock.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd lifted its position in Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after purchasing an additional 4,607 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth approximately $59,000. Guggenheim Capital LLC bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth approximately $61,000. R Squared Ltd bought a new position in shares of Taysha Gene Therapies in the first quarter worth approximately $50,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Taysha Gene Therapies in the first quarter worth $51,000. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Down 2.0%

TSHA opened at $5.97 on Tuesday. The stock has a market cap of $1.95 billion, a PE ratio of -14.21 and a beta of 1.22. The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. Taysha Gene Therapies has a 52 week low of $2.71 and a 52 week high of $7.30. The business’s fifty day simple moving average is $6.18 and its 200 day simple moving average is $5.56.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, research analysts expect that Taysha Gene Therapies will post -0.52 earnings per share for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.